Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

EKSO Stock Price Prediction Shows 1,676% Profit Potential

esko stocksEkso Bionics Holding (OTCBB: EKSO) stock has dipped 41% in the last three months and currently trades near $1.23 per share.

We're not worried about the price dip. EKSO stock is a still a long-term buy. In fact, this little-known stock has a profit potential of up to 1,676% in the next five years.

Ekso Bionics develops robotic exoskeletons. They're suits that allow people with severe mobility issues, stroke victims, and those with spinal trauma to walk again.

The reason EKSO stock has fallen recently has nothing to do with the company's financials or products. It came under an unjustified short attack last month that sent shares plummeting almost 25% in one day.

Fortunately for Money Morning readers, our Chief Investment Strategist Keith Fitz-Gerald explained the attack while it was happening…

The Short Attack on EKSO Stock

The type of attack that EKSO stock came under is called a "short and distort" scam.

"The perpetrators typically short the targeted company first, then release theoretically independent reports and analysis that is little more than a thinly veiled smear campaign," Fitz-Gerald said. "Once the stock has fallen, the parties involved buy to cover, bank their profits, and hopefully disappear."

The practice is illegal, but it still happens all the time.

kfg bio alternative investmentsThis time, the perpetrator was a blogger calling himself "The Pump Stopper," and he claimed that Ekso's partners now preferred competitors' products. He also pointed to a number of employee defections as a worrying sign. However, that's very common among startup companies.

"Less than an hour after I learned about the story, I was on the phone with Ekso's CEO Nathan Harding and CFO Max Scheder-Bieschin," Fitz-Gerald said. "As you might imagine, I share your concerns given the very serious nature of the allegations being made. So, I was keen to speak with them."

"I learned that the company would be issuing a point-by-point rebuttal to 'The Pump Stopper' to be posted on Ekso's website as soon as possible," he continued. "That way all interested parties – investors and 'The Pump Stopper' alike – would have access to it at the same time."

Fitz-Gerald said that is totally consistent with what he has seen from the company. Don't forget, it is fully compliant with all U.S. Securities and Exchange Commission regulations. Those include FD, Rule 10b5-1 and Rule 10b5-2 governing the release of material non-public information.

If you've been investing in EKSO, or are thinking about buying EKSO stock, the last thing you want to do is run because of this. Here's why the long-term outlook remains strong…

EKSO Stock's 1,600% Profit Potential

Join the conversation. Click here to jump to comments…

  1. Tim R | July 3, 2015

    My father was the founder/CEO of Datahand, a keyboard company. He had a study published by a Harvard Professor in ergonomics claiming it was faster than typing normally and also led to much fewer injuries. A few months later, a study was commissioned that claimed the precise opposite, however the people who reported it didn't have any background in the field, and was funded by an opposing force. It basically caused the company to struggle, and the cheaper model never really came.

    This recent attack reminds me of the excruciating resistance he faced. With 2 huge differences. First, this product's learning curve is more approachable. It might be hard to use, but the will power is there. Whereas people won't do effort to switch to a better keyboard until after they are injured by carpal tunnel. Point two is that I think the social implications of being able to walk again outweigh faster typing.

    I'm sure they will be able to rebound. My only real worry is stock dilution based on how many additional shares they plan on selling.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK